Biomodulatory therapy approach with lenalidomide in combination with pioglitazone, dexamethasone, and metronomic low-dose chemotherapy with treosulfan in patients with relapsed/refractory multiple myeloma > second-line.

Daniel Heudobler,Tanja Elger,Stephanie Mayer,Christina Hart,Martin Vogelhuber,Matthias Grube,Joachim Hahn,Florian Lüke,Diana Ditz,Andreas Günther,Martin Gramatzki,Burkhard Schmidt,Peter Ferenczy,Wolfgang Herr,Michael Rechenmacher,Albrecht Reichle

Biomodulatory therapy approach with lenalidomide in combination with pioglitazone, dexamethasone, and metronomic low-dose chemotherapy with treosulfan in patients with relapsed/refractory multiple myeloma > second-line.

2019

Daniel Heudobler
Tanja Elger
Stephanie Mayer
Christina Hart
Martin Vogelhuber
Matthias Grube
Joachim Hahn
Florian Lüke
Diana Ditz
Andreas Günther
Martin Gramatzki
Burkhard Schmidt
Peter Ferenczy
Wolfgang Herr
Michael Rechenmacher
Albrecht Reichle

8037Background: Nowadays, therapy for relapsed or refractory multiple myeloma (rrMM) usually consists of multi-targeted combination regimens for achieving complete remission. In this context, resis...

Keywords:

Oncology
Low-dose chemotherapy
Pioglitazone
Pathology
Dexamethasone
Refractory Multiple Myeloma
Lenalidomide
Medicine
Treosulfan
Internal medicine
Multiple myeloma
second line
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations